The breast cancer data set published by the “Royal College of Pathologists” has stated that assessment of PR receptor status in breast cancer is optional, primarily due to its uncertain predictive value in adjuvant therapy when compared with ER expression. This evidence concerns the gene ESR1 and breast carcinoma.